Novo Nordisk Statistics
Novo Nordisk (NOV) Stock Statistics & Valuation Metrics
Total Valuation
Novo Nordisk has a market cap or net worth of CHF 149.40B. The enterprise value is CHF 1.21T.
- Market Cap
- CHF 149.40B
- Enterprise Value
- CHF 1.21T
Share Statistics
Novo Nordisk has 3,390,128,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 3,390,128,000
- Owned by Insiders
- 0.01%
- Owned by Institutions
- 24.92%
Financial Efficiency
Novo Nordisk’s return on equity (ROE) is 0.70 and return on invested capital (ROIC) is 38.99%.
- Return on Equity (ROE)
- 0.70
- Return on Assets (ROA)
- 0.22
- Return on Invested Capital (ROIC)
- 38.99%
- Return on Capital Employed (ROCE)
- 0.52
- Revenue Per Employee
- 4.22M
- Profits Per Employee
- 1.47M
- Employee Count
- 68,794
- Asset Turnover
- 0.62
- Inventory Turnover
- 1.09
Valuation Ratios
The current PE Ratio of Novo Nordisk is 38.27. Novo Nordisk’s PEG ratio is 2.14.
- PE Ratio
- 38.27
- PS Ratio
- 12.01
- PB Ratio
- 25.45
- Price to FCF
- 33.13
- Price to Operating Cash Flow
- 26.94
- PEG Ratio
- 2.14
Income Statement
In the last 12 months, Novo Nordisk had revenue of 290.40B and earned 100.99B in profits. Earnings per share was 22.67.
- Revenue
- 290.40B
- Gross Profit
- 245.88B
- Operating Income
- 128.34B
- Pretax Income
- 127.19B
- Net Income
- 100.99B
- EBITDA
- 137.68B
- Earnings Per Share (EPS)
- 22.67
Cash Flow
In the last 12 months, operating cash flow was 131.25B and capital expenditures -56.50B, giving a free cash flow of 74.74B billion.
- Operating Cash Flow
- 131.25B
- Free Cash Flow
- 74.74B
- Free Cash Flow per Share
- 14.16
Dividends & Yields
Novo Nordisk pays an annual dividend of ―, resulting in a dividend yield of 3.97%
- Dividend Per Share
- ―
- Dividend Yield
- 3.97%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 3.02%
- Earnings Yield
- 2.61%
Stock Price Statistics
- Beta
- ―
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 173.41
- 200-Day Moving Average
- 173.41
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
Novo Nordisk upcoming earnings date is Feb 03, 2027, Before Open (Not Confirmed).
- Last Earnings Date
- Nov 04, 2026
- Next Earnings Date
- Feb 03, 2027
- Ex-Dividend Date
- ―
Financial Position
Novo Nordisk as a current ratio of 0.74, with Debt / Equity ratio of 71.64%
- Current Ratio
- 0.74
- Quick Ratio
- 0.55
- Debt to Market Cap
- 0.03
- Net Debt to EBITDA
- 0.63
- Interest Coverage Ratio
- 66.53
Taxes
In the past 12 months, Novo Nordisk has paid 26.20B in taxes.
- Income Tax
- 26.20B
- Effective Tax Rate
- 0.21
Enterprise Valuation
Novo Nordisk EV to EBITDA ratio is 27.98, with an EV/FCF ratio of 33.34.
- EV to Sales
- 12.08
- EV to EBITDA
- 27.98
- EV to Free Cash Flow
- 33.34
- EV to Operating Cash Flow
- 27.10
Balance Sheet
Novo Nordisk has CHF 41.55B in cash and marketable securities with CHF 118.72B in debt, giving a net cash position of -CHF 77.17B billion.
- Cash & Marketable Securities
- CHF 41.55B
- Total Debt
- CHF 118.72B
- Net Cash
- -CHF 77.17B
- Net Cash Per Share
- -CHF 22.76
- Tangible Book Value Per Share
- CHF 6.57
Margins
Gross margin is 83.92%, with operating margin of 42.28%, and net profit margin of 31.38%.
- Gross Margin
- 83.92%
- Operating Margin
- 42.28%
- Pretax Margin
- 39.03%
- Net Profit Margin
- 31.38%
- EBITDA Margin
- 43.18%
- EBIT Margin
- 39.45%
Analyst Forecast
The average price target for Novo Nordisk is CHF 35.60, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- CHF 35.60
- Price Target Upside
- 79.47% Downside
- Analyst Consensus
- Neutral
- Analyst Count
- 13
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
